meta
|
Preg
- medecines during pregnancy KB
Search
Sumatriptan
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Shuhaiber (Control unexposed, disease free), 1998 Källén (Controls unexposed, disease free), 2011 Nezvalová-Henriksen (Control unexposed, sick), 2013 Ephross (Control exposed to Naratriptan), 2014 Yusuf (Control exposed to Naratriptan), 2018
5
1.00
[
0.87
; 1.14]
57,007
4,840
not evaluable
Major congenital malformations
Shuhaiber (Control unexposed, disease free), 1998 Nezvalová-Henriksen (Control unexposed, sick), 2013 Ephross (Control exposed to Naratriptan), 2014 Yusuf (Control exposed to Naratriptan), 2018
4
1.07
[
0.39
; 2.88]
122
2,583
not evaluable
Congenital heart defects
De Jonge, 2013
1
2.31
[
0.84
; 6.39]
873
62
not evaluable
Digestive system anomalies
De Jonge, 2013
1
0.70
[
0.04
; 11.34]
362
58
not evaluable
Genital anomalies
De Jonge, 2013
1
0.81
[
0.05
; 13.08]
314
58
not evaluable
Limb defects
De Jonge, 2013
1
1.37
[
0.08
; 22.33]
184
58
not evaluable
Minor congenital malformations
O'Quinn, 1999
1
0.12
[
0.01
; 2.29]
4
67
not evaluable
Nervous system anomalies
De Jonge, 2013
1
1.22
[
0.07
; 19.75]
208
58
not evaluable
Oro-facial clefts
De Jonge, 2013
1
0.86
[
0.05
; 13.97]
294
58
not evaluable
Growth parameters and prematurity
Preterm (< 37 weeks)
Shuhaiber (Control unexposed, disease free), 1998 Olesen (Control unexposed, sick), 2000 Nezvalová-Henriksen (Control unexposed, sick), 2013
3
1.60
[
0.43
; 5.97]
103
691
not evaluable
Low birth weight (< 2500g)
Olesen (Control unexposed, sick), 2000 Kallen, 2001 Nezvalová-Henriksen (Control unexposed, sick), 2013
3
0.92
[
0.64
; 1.33]
80
1,267
not evaluable
Small for gestational age (weight)
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.88
[
0.56
; 1.40]
82
575
not evaluable
Very low birth weight (< 1500g)
Kallen, 2001
1
0.73
[
0.10
; 5.40]
-
658
not evaluable
Maternal consequences
Caesarean
Shuhaiber (Control unexposed, disease free), 1998
1
1.53
[
0.74
; 3.16]
38
80
not evaluable
Postpartum hemorrhage
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.49
[
0.25
; 0.96]
82
104
not evaluable
Neonatal disorders
Neonatal medical care
Nezvalová-Henriksen (Control unexposed, sick), 2013
1
0.39
[
0.15
; 1.01]
47
104
not evaluable
Intrauterine deaths
Early intrauterine death (< 22 weeks)
Shuhaiber (Control unexposed, disease free), 1998 O'Quinn, 1999 Ephross (Control exposed to Naratriptan), 2014 Yusuf (Control exposed to Naratriptan), 2018
4
1.06
[
0.68
; 1.67]
735
4,196
not evaluable
Elective/induced termination of pregnancy
O'Quinn, 1999 Ephross (Control exposed to Naratriptan), 2014 Yusuf (Control exposed to Naratriptan), 2018
3
1.02
[
0.50
; 2.05]
162
4,198
not evaluable
Late intrauterine deaths (> 22 weeks)
O'Quinn, 1999 Ephross (Control exposed to Naratriptan), 2014 Yusuf (Control exposed to Naratriptan), 2018
3
0.91
[
0.16
; 5.06]
20
4,198
not evaluable
Ectopic pregnancy
O'Quinn, 1999
1
1.21
[
0.07
; 19.73]
2
76
not evaluable
Perinatal death
Kallen, 2001
1
1.23
[
0.40
; 3.80]
-
658
not evaluable
0.0
50.0
1.0
